Skip to main content

Table 2 Characteristics of the study population

From: Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case–control study

  Traditional nonselective NSAIDs (n = 12,418) Celecoxib (n = 42,422) Rofecoxib (n = 25,674)
Age (years)    
   18–34 18.6 3.7 6.7
   35–44 15.8 6.5 9.7
   45–54 13.2 9.9 12.1
   55–64 13.5 15.9 16.4
   65–74 18.8 30.5 27.1
   75–84 15.1 27.1 22.7
   85+ 4.1 6.5 5.1
Sex    
   Female 55.4 67.4 65.5
   Male 44.6 32.6 34.5
Income level    
   Low 14.8 10.9 11.4
   Nonlow 85.2 89.1 88.6
Dosage category    
   High 11.6 31.2 8.8
   Standard 66.3 65.3 73.0
   Low 22.1 3.4 18.2
Prior diagnosis of gastropathy 3.6 7.7 5.0
Prior gastrointestinal procedures 2.0 4.5 2.7
Prior dispensation of gastroprotective agents 14.0 29.9 24.3
Prior referral to a gastroenterologist 2.8 6.0 3.9
History of NSAID use    
   Recent, first time 3.0 2.2 2.8
   Recent, chronic 6.6 4.3 4.2
   >1 to 3 months 15.7 7.8 6.3
   >3 to 12 months 19.4 22.0 14.0
   No use 55.2 63.7 72.8
Anticoagulants 1.3 3.3 3.0
Corticosteroids 11.7 19.6 16.9
Benzodiazepines 23.3 38.2 33.0
Antidepressants 10.5 17.2 15.7
Chronic Disease Score    
   ≥10 5.2 10.3 8.2
   5–9 19.6 28.6 25.4
   1–4 27.9 33.6 32.6
   0 47.3 27.6 33.8
Prescriber specialty    
   General practitioner 85.9 85.3 88.3
   Cardiology 1.0 0.4 0.3
   Internal Medicine 2.3 3.3 2.1
   Neurology 0.3 0.3 0.2
   General surgery 1.4 0.8 1.0
   Obstetrics/gynaecology 1.5 0.2 0.3
   Orthopaedic surgery 1.2 3.4 3.2
   Rheumatology 2.5 2.5 1.7
   Other 2.8 3.8 2.9
  1. Values are expressed as percentages. NSAID, nonsteroidal anti-inflammatory drug.